Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entinostat and Exemestane DDI Study in ER+ Breast Cancer
NCT02820961Phase 1Completed
- Sponsor
- Syndax Pharmaceuticals
- Start
- Jun 2016
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of entinostat in estrogen receptor-positive breast cancer (ER+) (2 cohorts), sponsored by Syndax Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration at 1 year, Time to Maximum Plasma Concentration at 1 year and 4 more. Started Jun 2016; status: completed.
02
Drugs
entinostat
03
Conditions
estrogen receptor-positive breast cancer (ER+)
Beyond the preview
Go deeper on NCT02820961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02820961.